Aryl Hydrocarbon Receptor Antagonists Mitigate the Effects of Dioxin on Critical Cellular Functions in

Chawon Yun1,2, Karina M Katchko3,4, Michael S Schallmo5,6

  • 1Department of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. yunchawon@hotmail.com.

Insights

Aryl hydrocarbon receptor (AhR) activation by dioxin inhibits human bone healing by impairing osteogenic differentiation, cell adhesion, and migration. AhR antagonists show potential for protecting against these negative effects in smokers.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Orthopedics

Background:

  • Cigarette smoking inhibits human bone healing through unclear mechanisms.
  • The aryl hydrocarbon receptor (AhR) is implicated in mediating these anti-osteogenic effects.
  • 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD, dioxin) is a potent AhR ligand used to study AhR activation.

Purpose of the Study:

  • To investigate the effects of AhR activation on osteogenic differentiation, cell adhesion, and migration in a human osteoblast-like cell line.
  • To explore the potential of AhR antagonists in mitigating dioxin's adverse effects on bone cells.

Main Methods:

  • Utilized dioxin as a prototype AhR ligand to activate the receptor in human osteoblast-like cells.
  • Assessed effects on pro-osteogenic biomarkers, cell adhesion (integrin, cadherin), and cell migration (CXCR4, CXCL12).
  • Evaluated the protective capacity of AhR antagonists against dioxin-induced changes.

Main Results:

  • Dioxin significantly inhibited osteogenic differentiation and negatively impacted cell adhesion and migration.
  • Dioxin reduced the expression of integrin, cadherin, CXCR4, and CXCL12.
  • Co-treatment with AhR antagonists protected against dioxin's inhibitory actions and restored cell function.

Conclusions:

  • AhR activation plays a role in impaired bone regeneration in humans exposed to AhR activators like those in cigarette smoke.
  • Findings in human cells align with previous murine studies, suggesting animal models' relevance.
  • The AhR presents a potential therapeutic target for individuals exposed to environmental aryl hydrocarbons, including cigarette smoke.

Related Concept Videos

Cellular Differentiation00:57

Cellular Differentiation

How does a complex organism such as a human develop from a single cell? It all starts from a single fertilized egg which gives rise to a vast array of cell types, such as nerve cells, muscle cells, and epithelial cells that characterize the adult? Throughout development and adulthood, cellular differentiation leads cells to assume their final morphology and physiology. Differentiation is the process by which unspecialized cells become specialized to carry out distinct functions.
A zygote is a...
5.6K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Functional Groups02:45

Functional Groups

Functional groups are a group of atoms with characteristic properties, which when linked to the carbon skeleton of a molecule, alter the properties of that molecule. For example, the presence of certain functional groups on a molecule will make them hydrophilic, whereas others will make them hydrophobic. These functional groups are an indispensable part of organic chemistry and important components of biological molecules, such as carbohydrates, proteins, lipids, and nucleic acids. Each...
89.7K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K